Long‐term follow‐up of children with risk organ‐negative Langerhans cell histiocytosis after 2‐chlorodeoxyadenosine treatment

Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review

(2020) Antoine Néel et al.   BRITISH JOURNAL OF HAEMATOLOGY

Clinical responses and persistent BRAFV600E+ blood cells in children with LCH treated with MAPK pathway inhibition

(2019) Olive S. Eckstein et al.   BLOOD

Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study

(2019) Jean Donadieu et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study

(2018) Sébastien Héritier et al.   BRITISH JOURNAL OF HAEMATOLOGY

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

(2016) J.-F. Emile et al.   BLOOD

Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age

(2016) Charlotte Rigaud et al.   BRITISH JOURNAL OF HAEMATOLOGY

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy

(2016) Sébastien Héritier et al.   JOURNAL OF CLINICAL ONCOLOGY

Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study

(2015) J. Donadieu et al.   BLOOD

Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis

(2015) S. Barete et al.   BLOOD

Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?

(2014) Marie-Luise Berres et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cladribine improves lung cysts and pulmonary function in a child with histiocytosis

(2014) Ralph Epaud et al.   EUROPEAN RESPIRATORY JOURNAL

Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis

(2014) Vincent Grobost et al.   Orphanet Journal of Rare Diseases

2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells

(2013) V. Singh et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years

(2012) Riccardo Haupt et al.   PEDIATRIC BLOOD & CANCER

Severe persistent bone marrow failure following therapy with 2-chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brain

(2011) Kayo Yamada et al.   PEDIATRIC BLOOD & CANCER

Recurrent BRAF mutations in Langerhans cell histiocytosis

(2010) G. Badalian-Very et al.   BLOOD

2′-chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the histiocyte society

(2009) Sheila Weitzman et al.   PEDIATRIC BLOOD & CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004

(2008) Aurélie Guyot-Goubin et al.   PEDIATRIC BLOOD & CANCER

Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine

(2007) Girish Dhall et al.   PEDIATRIC BLOOD & CANCER